BGBIO - nye positive data presenteres i oktober
BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32nd ENA SYMPOSIUM
Bergen, Norway, 14 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that pre-clinical data on tilvestamab, the Company’s novel function blocking, humanized anti-AXL antibody, will be presented at an ePoster presentation at the virtual 32nd EORTC NCI AACR (ENA) Symposium.
The data presented shows that tilvestamab prevents AXL mediated cell signaling in cancer cell lines, reduces cell migration and invasion and shows anti-tumor efficacy in a panel of mouse xenograft models. Further it is shown that in a non-human primate dose-ranging toxicokinetic study, tilvestamab was well tolerated during dosing phase up to the highest studied dose of 25mg/kg. Tilvestamab is currently being evaluated in a Phase I clinical study (BGB149-101; NCT03795142) in healthy volunteers to evaluate safety, tolerability and pharmacokinetics.
The meeting will run from October 24-25 2020 and will be fully virtual, with further information available on the ENA website. Full details of the abstract are as follows:
Title: Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
Date: Saturday, October 24th 2020
Link to Abstract
– END –
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying many life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
Bergen, Norway, 14 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that pre-clinical data on tilvestamab, the Company’s novel function blocking, humanized anti-AXL antibody, will be presented at an ePoster presentation at the virtual 32nd EORTC NCI AACR (ENA) Symposium.
The data presented shows that tilvestamab prevents AXL mediated cell signaling in cancer cell lines, reduces cell migration and invasion and shows anti-tumor efficacy in a panel of mouse xenograft models. Further it is shown that in a non-human primate dose-ranging toxicokinetic study, tilvestamab was well tolerated during dosing phase up to the highest studied dose of 25mg/kg. Tilvestamab is currently being evaluated in a Phase I clinical study (BGB149-101; NCT03795142) in healthy volunteers to evaluate safety, tolerability and pharmacokinetics.
The meeting will run from October 24-25 2020 and will be fully virtual, with further information available on the ENA website. Full details of the abstract are as follows:
Title: Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
Date: Saturday, October 24th 2020
Link to Abstract
– END –
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying many life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
Redigert 20.01.2021 kl 21:03
Du må logge inn for å svare
Nanoq
14.10.2020 kl 07:29
969
God nyhet. Her er litt mer om dette:
Abstract title:
Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000897260
Abstract title:
Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000897260
Redigert 20.01.2021 kl 21:03
Du må logge inn for å svare
Agurknytt
14.10.2020 kl 07:26
993
Blir spennende!
Noen som kan si noe om tilvestamab sammenlignet med Bemcentinib? Flere mulige bivirkninger med tilvestamab?
Noen som kan si noe om tilvestamab sammenlignet med Bemcentinib? Flere mulige bivirkninger med tilvestamab?
Redigert 20.01.2021 kl 21:03
Du må logge inn for å svare